Inhibitors of NO-synthases
The substances of the invention are highly effective low-molecular NO-synthases inhibitors. They can be synthesised easily and inexpensively in high purity via standard methods and exhibit selectivity for the bNOS present in the central nervous system which is involved in neuronal diseases as Alzheimer’s and Parkinson’s disease, multiple sclerosis and migraine. Thus, it is of particular importance that the inhibitors, after oral up-take and subsequent resorption via the intestinal epithelium, are able to cross the blood-brain barrier.
Further Information: PDF
Patent- und Verwertungsagentur für die Wissenschaftlichen Einrichtungen in Schleswig-Holstein GmbH (PVA SH)
Phone: +49 (0)431/8009937
Contact
Dr. Alexandra Baumgartner
Media Contact
All latest news from the category: Technology Offerings
Newest articles
NASA: Mystery of life’s handedness deepens
The mystery of why life uses molecules with specific orientations has deepened with a NASA-funded discovery that RNA — a key molecule thought to have potentially held the instructions for…
What are the effects of historic lithium mining on water quality?
Study reveals low levels of common contaminants but high levels of other elements in waters associated with an abandoned lithium mine. Lithium ore and mining waste from a historic lithium…
Quantum-inspired design boosts efficiency of heat-to-electricity conversion
Rice engineers take unconventional route to improving thermophotovoltaic systems. Researchers at Rice University have found a new way to improve a key element of thermophotovoltaic (TPV) systems, which convert heat…